NeoGenomics (NASDAQ:NEO – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Stephens in a research report issued on Tuesday, Benzinga reports. They presently have a $19.00 target price on the medical research company’s stock. Stephens’ price target indicates a potential upside of 11.76% from the stock’s current price.
A number of other research analysts have also weighed in on the company. Benchmark restated a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday. TD Cowen lowered their price objective on shares of NeoGenomics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, May 1st. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Tuesday. BTIG Research dropped their price target on NeoGenomics from $23.00 to $21.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Finally, Craig Hallum assumed coverage on NeoGenomics in a research report on Wednesday, May 1st. They issued a “buy” rating and a $26.00 price target for the company. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average price target of $19.89.
Check Out Our Latest Stock Analysis on NeoGenomics
NeoGenomics Price Performance
NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its quarterly earnings results on Monday, July 29th. The medical research company reported $0.03 earnings per share for the quarter. NeoGenomics had a negative return on equity of 3.54% and a negative net margin of 13.79%. The business had revenue of $164.50 million during the quarter, compared to the consensus estimate of $161.82 million. During the same period in the prior year, the company posted ($0.09) EPS. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. Analysts expect that NeoGenomics will post -0.21 earnings per share for the current fiscal year.
Hedge Funds Weigh In On NeoGenomics
Several hedge funds have recently bought and sold shares of the business. Louisiana State Employees Retirement System bought a new position in shares of NeoGenomics during the 4th quarter worth $1,032,000. Oak Family Advisors LLC grew its position in shares of NeoGenomics by 3.4% during the 4th quarter. Oak Family Advisors LLC now owns 99,978 shares of the medical research company’s stock worth $1,618,000 after buying an additional 3,241 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of NeoGenomics by 19.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,707 shares of the medical research company’s stock worth $497,000 after buying an additional 5,064 shares in the last quarter. Handelsbanken Fonder AB grew its position in shares of NeoGenomics by 7.0% during the 4th quarter. Handelsbanken Fonder AB now owns 19,900 shares of the medical research company’s stock worth $322,000 after buying an additional 1,300 shares in the last quarter. Finally, Jennison Associates LLC grew its position in shares of NeoGenomics by 17.8% during the 4th quarter. Jennison Associates LLC now owns 591,556 shares of the medical research company’s stock worth $9,571,000 after buying an additional 89,473 shares in the last quarter. Institutional investors own 98.50% of the company’s stock.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Articles
- Five stocks we like better than NeoGenomics
- Dividend Capture Strategy: What You Need to Know
- Aerospace Stock Fires Up a Solid EPS Beat and Raises Guidance
- P/E Ratio Calculation: How to Assess Stocks
- Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- This Semiconductor Stock Is ON Track for a New High
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.